NPPB and Hypertension: For example, the factors that typically indicate a moderate risk of cardiovascular toxicity during most cancer therapies include an LVEF between 50 to 54%, elevated baseline level of cTn or NT-proBNP, age of 65 to 79 years, hypertension, chronic kidney disease, diabetes mellitus, current or significant history of smoking, prior exposure to radiation therapy, or obesity with a body mass index exceeding 30 kg/m2.